Similar articles

• A pilot study of cidofovir in patients with kaposi sarcoma.

  Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, Pluda JM, Marshall V, Walters M, Welles L, Rodriguez-Chavez IR, Pittaluga S, Tosato G, Yarchoan R. Little RF, et al. J Infect Dis. 2003 Jan 1;187(1):149-53. doi: 10.1086/346159. Epub 2002 Dec 13. J Infect Dis. 2003. PMID: 12508160
• Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS.

  Mazzi R, Parisi SG, Sarmati L, Uccella I, Nicastri E, Carolo G, Gatti F, Concia E, Andreoni M. Mazzi R, et al. AIDS. 2001 Oct 19;15(15):2061-2. doi: 10.1097/00002030-200110190-00026. AIDS. 2001. PMID: 11600842 No abstract available.
• Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: report of a case.

  Simonart T, Noel JC, De Dobbeleer G, Parent D, Van Vooren JP, De Clercq E, Snoeck R. Simonart T, et al. J Med Virol. 1998 Jul;55(3):215-8. J Med Virol. 1998. PMID: 9624609
• A preclinical and clinical overview of the nucleotide-based antiviral agent cidofovir (HPMPC).

  Lalezari JP, Stagg RJ, Jaffe HS, Hitchcock MJ, Drew WL. Lalezari JP, et al. Adv Exp Med Biol. 1996;394:105-15. doi: 10.1007/978-1-4757-9209-6_12. Adv Exp Med Biol. 1996. PMID: 8815677 Review. No abstract available.
• Topical and intralesional cidofovir: a review of pharmacology and therapeutic effects.

  Zabawski EJ Jr, Cockerell CJ. Zabawski EJ Jr, et al. J Am Acad Dermatol. 1998 Nov;39(5 Pt 1):741-5. doi: 10.1016/s0190-9622(98)70046-5. J Am Acad Dermatol. 1998. PMID: 9810890 Review.